Transcend aftermath: Angiotensin ii type 1 receptor antagonists (angiotensin receptor blockers) at the clinical crossroad

Research output: Contribution to journalArticle

Abstract

The present article synthetically revisits the recent results of TRANSCEND, putting them in the context of other clinical trials conducted with ACE inhibitors or angiotensin II type 1 receptor antagonists (angiotensin receptor blockers ARBs) compared with placebo. Based on these premises, the article provides an original meta-analysis on the effects of ACE inhibitors and ARBs on stroke and on combined cardiovascular (e.g. 'HOPE endpoint') outcomes in high-risk patients. In summary, the results of this analysis provide evidence that both ACE inhibitors and ARBs effectively and significantly reduce the incidence of cardiovascular outcomes compared with best available standard treatment (placebo) in high-risk patients. In view of the fact that the results of TRANSCEND were obtained in ACE inhibitor-intolerant patients, antihypertensive therapy based on telmisartan can be regarded as a new therapeutic option for treating patients at high cardiovascular risk.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalHigh Blood Pressure and Cardiovascular Prevention
Volume16
Issue number1
DOIs
Publication statusPublished - 2009

Keywords

  • ACE inhibitors
  • Angiotensin II receptor blockers
  • Cardiovascular risk.
  • Hypertension
  • Stroke

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Fingerprint Dive into the research topics of 'Transcend aftermath: Angiotensin ii type 1 receptor antagonists (angiotensin receptor blockers) at the clinical crossroad'. Together they form a unique fingerprint.

  • Cite this